Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
Public ClinicalTrials.gov record NCT00575952. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the side effects and best dose of intraperitoneal paclitaxel when given together with doxorubicin hydrochloride and cisplatin in treating patients with stage III-IV endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells.
Study identification
- NCT ID
- NCT00575952
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 27 participants
Conditions and interventions
Conditions
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Mixed Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Endometrial Squamous Cell Carcinoma
- Endometrial Undifferentiated Carcinoma
- Recurrent Uterine Corpus Carcinoma
- Stage IIIA Uterine Corpus Cancer
- Stage IIIC Uterine Corpus Cancer
- Stage IVA Uterine Corpus Cancer
- Stage IVB Uterine Corpus Cancer
Interventions
- Cisplatin Drug
- Doxorubicin Hydrochloride Drug
- Filgrastim Biological
- Paclitaxel Drug
- Pegfilgrastim Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 17, 2008 (Actual)
- Primary completion
- Jul 16, 2016 (Actual)
- Completion
- Jul 16, 2016 (Actual)
- Last update posted
- Aug 24, 2017
2008 – 2016
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hartford Hospital | Hartford | Connecticut | 06102 | — |
| The Hospital of Central Connecticut | New Britain | Connecticut | 06050 | — |
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637 | — |
| University of Iowa/Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Cooper Hospital University Medical Center | Camden | New Jersey | 08103 | — |
| Case Western Reserve University | Cleveland | Ohio | 44106 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Women and Infants Hospital | Providence | Rhode Island | 02905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00575952, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 24, 2017 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00575952 live on ClinicalTrials.gov.